MDLA Records 12.6 Per Cent Net Profit Increase to Rp226 Billion in First Half of 2026
PT Medela Potentia Tbk (MDLA) recorded sales of Rp8.2 trillion in the first half of 2026, representing a 10.1 per cent growth compared to the same period the previous year.
This growth was accompanied by a 12.6 per cent increase in net profit to Rp226 billion, while gross profit reached Rp762 billion, up 6.8 per cent, and EBITDA grew by 11.2 per cent to Rp325 billion.
These performance figures were presented during a Public Expose Live held online on Tuesday, 8 September 2026, as part of the company’s information disclosure to investors and the public.
In its distribution division, the subsidiary PT Anugrah Argon Medica (AAM) continues to strengthen its business portfolio by adding five new principals, consisting of one ethical principal, three consumer health principals, and one medical device principal.
Meanwhile, in the medical device own-product line, the Stardec brand marketed by the subsidiary PT Djembatan Dua recorded a sales growth of 34 per cent. This growth was supported by portfolio expansion through the launch of Stardec DecaCare 5 Litre and Stardec DecaFoam.
The development of new products provides the Company with opportunities to expand the use of Stardec products while increasing the contribution of its own-product business. Stardec products were also exported to Cambodia and Timor-Leste in 2025, with plans for further exports in 2026.
The President Director of PT Medela Potentia Tbk (MDLA), Juliwaty, stated that the Company’s growth in the first half of 2026 reflects the strengthening position of Medela Potentia within Indonesia’s healthcare ecosystem.
“The growth of the healthcare business in Indonesia provides significant opportunities for the Company to continue developing. With an ecosystem encompassing distribution, medical devices, manufacturing, and digital services, we have the foundation to reach more customers while providing holistic healthcare solutions,” explained Juliwaty, as quoted from her statement on Tuesday, 8 September 2026.
The Company continues to strengthen its infrastructure capacity to capture growth opportunities in the demand for healthcare product distribution. The construction of the AAM Medan warehouse has reached 95 per cent and is targeted to begin operations in the fourth quarter of 2026, which will enhance distribution capabilities in the Sumatra region.
Furthermore, the company plans to construct a second National Distribution Centre (NDC 2) in 2027, which will focus on cold storage requirements. NDC 2 is planned to be built on a 2.7-hectare site within the Jababeka 2 Industrial Estate.